FR07C0046I1 - - Google Patents
Info
- Publication number
- FR07C0046I1 FR07C0046I1 FR07C0046C FR07C0046I1 FR 07C0046 I1 FR07C0046 I1 FR 07C0046I1 FR 07C0046 C FR07C0046 C FR 07C0046C FR 07C0046 I1 FR07C0046 I1 FR 07C0046I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9611098P | 1998-08-10 | 1998-08-10 | |
US13135299P | 1999-04-28 | 1999-04-28 | |
PCT/US1999/018149 WO2000009531A2 (fr) | 1998-08-10 | 1999-08-10 | β-L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B |
Publications (2)
Publication Number | Publication Date |
---|---|
FR07C0046I1 true FR07C0046I1 (fr) | 2007-10-26 |
FR07C0046I2 FR07C0046I2 (fr) | 2008-05-09 |
Family
ID=26791121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR07C0046C Active FR07C0046I2 (fr) | 1998-08-10 | 2007-09-21 | Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b |
Country Status (22)
Country | Link |
---|---|
US (5) | US6395716B1 (fr) |
EP (2) | EP1104436B1 (fr) |
JP (2) | JP4294870B2 (fr) |
KR (4) | KR100568035B1 (fr) |
CN (3) | CN100482236C (fr) |
AT (1) | ATE313550T1 (fr) |
AU (1) | AU5475799A (fr) |
BR (1) | BRPI9912896B8 (fr) |
CA (1) | CA2340156C (fr) |
CY (2) | CY2007017I2 (fr) |
DE (2) | DE69929060T2 (fr) |
DK (3) | DK1431304T3 (fr) |
ES (3) | ES2255295T3 (fr) |
FR (1) | FR07C0046I2 (fr) |
HK (3) | HK1034083A1 (fr) |
LU (1) | LU91348I2 (fr) |
MX (1) | MXPA01001507A (fr) |
NL (1) | NL300286I2 (fr) |
PT (2) | PT1431304E (fr) |
RU (1) | RU2424016C2 (fr) |
SG (1) | SG132498A1 (fr) |
WO (1) | WO2000009531A2 (fr) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE346651T1 (de) * | 1995-06-07 | 2006-12-15 | Univ Emory | Nucleoside mit anti-hepatitis b virus wirksamkeit |
AU5475799A (en) | 1998-08-10 | 2000-03-06 | Centre National De La Recherche Scientifique | Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis |
US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
EP1600452A3 (fr) | 1999-11-12 | 2008-09-10 | Pharmasset, Inc. | Synthèse de 2'-déoxy-L-nucléosides |
EP1232166A2 (fr) * | 1999-11-12 | 2002-08-21 | Pharmasset Limited | Synthese de 2'-deoxy-l-nucleosides |
DK1267880T4 (da) * | 2000-02-29 | 2010-05-17 | Bristol Myers Squibb Co | Entecavir-formulering med lav dosis og anvendelse deraf |
US20020056123A1 (en) * | 2000-03-09 | 2002-05-09 | Gad Liwerant | Sharing a streaming video |
US6822089B1 (en) * | 2000-03-29 | 2004-11-23 | Isis Pharmaceuticals, Inc. | Preparation of deoxynucleosides |
WO2001079246A2 (fr) * | 2000-04-13 | 2001-10-25 | Pharmasset, Ltd. | Derives de nucleoside substitues par 3'- ou 2'-hydroxymethyle utilises dans le traitement des infections imputables au virus de l'hepatite |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
AU2001272923A1 (en) * | 2000-05-26 | 2001-12-11 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
CA2410488C (fr) | 2000-05-26 | 2009-10-27 | Idenix (Cayman) Limited | Procedes de traitement de l'infection virale hepatite delta en utilisant le .beta.-l-2' deoxy-nucleosides |
US6787526B1 (en) * | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
MY141594A (en) * | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
CN101250194B (zh) * | 2000-11-29 | 2011-05-04 | 三井化学株式会社 | L-核酸衍生物及其合成方法 |
CN102241720B (zh) * | 2000-11-29 | 2014-01-29 | 三井化学株式会社 | L-核酸衍生物及其合成方法 |
AU2002360697B2 (en) | 2001-12-20 | 2009-04-23 | Beth Israel Deaconess Medical Center | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation |
EP1458735A2 (fr) * | 2001-12-21 | 2004-09-22 | Micrologix Biotech, Inc. | 7-deaza l-nucleosides en tant qu'antiviraux |
EP1485395A4 (fr) * | 2002-02-28 | 2011-04-13 | Biota Scient Management | Mimetiques nucleotidiques et leurs promedicaments |
PL373758A1 (en) * | 2002-06-27 | 2005-09-05 | Medivir Ab | Synergistic interaction of abacavir and alovudine |
RS114104A (en) | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited, | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CN103319554A (zh) | 2002-06-28 | 2013-09-25 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
US7662798B2 (en) * | 2002-06-28 | 2010-02-16 | Idenix Pharmaceuticals, Inc. | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
TWI244393B (en) * | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
CN100536853C (zh) * | 2002-09-13 | 2009-09-09 | 艾登尼科斯(开曼)有限公司 | β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗 |
MXPA05004504A (es) | 2002-10-31 | 2005-08-16 | Metabasis Therapeutics Inc | Nuevos di-esteres de fosfato ciclicos de 1,3-propano-1-aril-dioles y su uso en la preparacion de profarmacos. |
JP2006519753A (ja) | 2002-11-15 | 2006-08-31 | イデニクス(ケイマン)リミテツド | 2’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異 |
ES2470771T3 (es) * | 2002-12-12 | 2014-06-24 | Idenix Pharmaceuticals, Inc | Procedimiento para la producción de nucle�sidos ramificados en 2' |
WO2004084453A2 (fr) * | 2003-03-20 | 2004-09-30 | Microbiologica Quimica E Farmaceutica Ltd. | Procedes de fabrication de 2'-desoxy-$g(b)-l-nucleosides |
KR20060015542A (ko) * | 2003-04-28 | 2006-02-17 | 이데닉스 (케이만) 리미티드 | 산업 규모의 뉴클레오시드 합성 |
WO2004096197A2 (fr) * | 2003-05-02 | 2004-11-11 | Universita Degli Studi Di Cagliari | 5-aza-7-deazapurine nucleosides pour le traitement de flaviviridae |
SI2604620T1 (sl) | 2003-05-30 | 2016-10-28 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Modificirani fluorirani nukleozidni analogi |
CA2531412A1 (fr) * | 2003-06-30 | 2005-01-13 | Idenix (Cayman) Limited | Synthese de nucleosides b-l-2-desoxy |
CN1315863C (zh) * | 2003-12-12 | 2007-05-16 | 河南省科学院质量检验与分析测试研究中心 | β-L-2'-脱氧-核苷衍生物、其合成方法及其药物用途 |
PT3109244T (pt) | 2004-09-14 | 2019-06-04 | Gilead Pharmasset Llc | ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados |
JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
EP1976382B1 (fr) * | 2005-12-23 | 2013-04-24 | IDENIX Pharmaceuticals, Inc. | Procede pour la preparation d'un intermediaire synthetique pour la preparation de nucleosides ramifies |
UA100666C2 (uk) | 2006-04-11 | 2013-01-25 | Новартіс Аг | Інгібітори нсv/віл та їх застосування |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US20090082306A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telbivudine |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
WO2010075517A2 (fr) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Analogues de nucléoside |
MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
MX2012005601A (es) * | 2009-11-16 | 2012-08-01 | Univ Georgia | Nucleosidos carboxiclicos de 2'-fluoro-6'-metileno y metodos para tratar infecciones virales. |
HUE034239T2 (en) | 2010-03-31 | 2018-02-28 | Gilead Pharmasset Llc | Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t |
US9011833B2 (en) | 2010-10-08 | 2015-04-21 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
EP2646453A1 (fr) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Composés |
CN102649788B (zh) * | 2011-02-28 | 2015-03-25 | 四川大学 | β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途 |
DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
EP4005560A1 (fr) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Formulation de combinaison de deux composés antiviraux |
CN114404427A (zh) | 2014-02-13 | 2022-04-29 | 配体药物公司 | 前药化合物及其用途 |
JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
CN110680806A (zh) * | 2018-07-04 | 2020-01-14 | 郑州泰丰制药有限公司 | 一种替比夫定颗粒的制备方法 |
CN108570078A (zh) * | 2018-07-18 | 2018-09-25 | 荆门医药工业技术研究院 | 一种制备1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖的方法 |
CN114133398B (zh) * | 2021-12-31 | 2022-11-22 | 中南民族大学 | 氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB875971A (en) | 1959-01-14 | 1961-08-30 | Hoffmann La Roche | A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4916122A (en) | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
US5190926A (en) | 1987-01-28 | 1993-03-02 | University Of Georgia Research Foundation, Inc. | 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents |
GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質 |
US6020322A (en) | 1993-11-09 | 2000-02-01 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
KR890701609A (ko) | 1987-10-28 | 1989-12-21 | 원본미기재 | 아실 데옥시리보뉴클레오시드 유도체 및 그의 사용 |
JP2675864B2 (ja) | 1988-07-05 | 1997-11-12 | キヤノン株式会社 | 被記録材及びこれを用いたインクジェット記録方法 |
SE8802687D0 (sv) * | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
WO1991018914A1 (fr) | 1990-05-29 | 1991-12-12 | Vical, Inc. | Synthese de derives de diphosphate et de triphosphate de glycerine |
DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
DE69024978T2 (de) | 1990-07-12 | 1996-12-12 | G Drill Ab | Gesteinsbohrgerät mit hydraulischem antrieb im bohrloch |
DE69129650T2 (de) * | 1990-09-14 | 1999-03-25 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
US5206244A (en) * | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
IT1246983B (it) * | 1990-11-13 | 1994-12-12 | Consiglio Nazionale Ricerche | L-2'-desossiuridine e composizioni farmaceutiche che le contengono. |
IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
DE69233693T2 (de) | 1991-03-06 | 2008-01-24 | Emory University | Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B |
US5220003A (en) | 1991-03-29 | 1993-06-15 | The Regents Of The University Of California | Process for the synthesis of 2',3'-dideoxynucleosides |
WO1992018517A1 (fr) | 1991-04-17 | 1992-10-29 | Yale University | Procede de traitement ou de prevention du virus de l'hepatite b |
CA2112803A1 (fr) | 1991-07-12 | 1993-01-21 | Karl Y. Hostetler | Liponucleosides antiviraux: traitement de l'hepatite b |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
WO1994020523A1 (fr) * | 1993-03-10 | 1994-09-15 | The Wellcome Foundation Limited | Ciblage de tumeur au moyen de conjugues oligonucleotidiques l-enantiomeres d'immunoreactifs et de radionucleides chelates |
JP3693357B2 (ja) | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
WO1994026273A1 (fr) | 1993-05-12 | 1994-11-24 | Hostetler Karl Y | Derives d'acyclovir a usage topique |
US5627160A (en) * | 1993-05-25 | 1997-05-06 | Yale University | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
CA2637774C (fr) | 1993-09-10 | 2011-07-19 | Emory University | Nucleosides avec activite virale anti-hepatite b |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
WO1996011204A1 (fr) * | 1994-10-07 | 1996-04-18 | Max-Delbrück-Centrum für Molekulare Medizin | NOUVEAUX β-L-NUCLEOSIDES ET LEUR UTILISATION |
US5559101A (en) * | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
ATE346651T1 (de) * | 1995-06-07 | 2006-12-15 | Univ Emory | Nucleoside mit anti-hepatitis b virus wirksamkeit |
US6025335A (en) | 1995-09-21 | 2000-02-15 | Lipitek International, Inc. | L-Nucleoside Dimer Compounds and therapeutic uses |
EP1069903A1 (fr) * | 1998-03-11 | 2001-01-24 | Lipitek International, Inc. | Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies |
CA2335617C (fr) | 1998-06-24 | 2009-12-15 | Emory University | 3'-azido-2',3'-dideoxyuridine (cs-87) utilise en combinaison avec d'autres medicaments anti-vih pour la fabrication d'un medicament destine a traiter le vih |
US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
AU5475799A (en) * | 1998-08-10 | 2000-03-06 | Centre National De La Recherche Scientifique | Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US6787526B1 (en) * | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
AU2001272923A1 (en) * | 2000-05-26 | 2001-12-11 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
CA2410488C (fr) * | 2000-05-26 | 2009-10-27 | Idenix (Cayman) Limited | Procedes de traitement de l'infection virale hepatite delta en utilisant le .beta.-l-2' deoxy-nucleosides |
-
1999
- 1999-08-10 AU AU54757/99A patent/AU5475799A/en not_active Abandoned
- 1999-08-10 ES ES99941027T patent/ES2255295T3/es not_active Expired - Lifetime
- 1999-08-10 RU RU2006147216/04A patent/RU2424016C2/ru active Protection Beyond IP Right Term
- 1999-08-10 JP JP2000564981A patent/JP4294870B2/ja not_active Expired - Lifetime
- 1999-08-10 BR BRPI9912896A patent/BRPI9912896B8/pt not_active IP Right Cessation
- 1999-08-10 KR KR1020057009515A patent/KR100568035B1/ko not_active IP Right Cessation
- 1999-08-10 CN CNB021265739A patent/CN100482236C/zh not_active Expired - Lifetime
- 1999-08-10 EP EP99941027A patent/EP1104436B1/fr not_active Expired - Lifetime
- 1999-08-10 SG SG200302078-1A patent/SG132498A1/en unknown
- 1999-08-10 MX MXPA01001507A patent/MXPA01001507A/es active IP Right Grant
- 1999-08-10 US US09/371,747 patent/US6395716B1/en not_active Expired - Lifetime
- 1999-08-10 DK DK04075926T patent/DK1431304T3/en active
- 1999-08-10 DE DE69929060T patent/DE69929060T2/de not_active Expired - Lifetime
- 1999-08-10 CA CA002340156A patent/CA2340156C/fr not_active Expired - Lifetime
- 1999-08-10 DE DE200712000062 patent/DE122007000062I1/de active Pending
- 1999-08-10 CN CNB2004100028639A patent/CN100387237C/zh not_active Expired - Lifetime
- 1999-08-10 CN CNB998095532A patent/CN1257912C/zh not_active Expired - Lifetime
- 1999-08-10 KR KR1020067007301A patent/KR100691737B1/ko not_active IP Right Cessation
- 1999-08-10 ES ES04075926.8T patent/ES2531928T3/es not_active Expired - Lifetime
- 1999-08-10 PT PT4075926T patent/PT1431304E/pt unknown
- 1999-08-10 EP EP10184657.4A patent/EP2415776B1/fr not_active Expired - Lifetime
- 1999-08-10 ES ES10184657.4T patent/ES2579903T3/es not_active Expired - Lifetime
- 1999-08-10 PT PT101846574T patent/PT2415776T/pt unknown
- 1999-08-10 DK DK10184657.4T patent/DK2415776T3/en active
- 1999-08-10 DK DK99941027T patent/DK1104436T3/da active
- 1999-08-10 KR KR1020067007304A patent/KR100702230B1/ko not_active IP Right Cessation
- 1999-08-10 AT AT99941027T patent/ATE313550T1/de active
- 1999-08-10 KR KR1020017001758A patent/KR100634342B1/ko active IP Right Grant
- 1999-08-10 WO PCT/US1999/018149 patent/WO2000009531A2/fr active IP Right Grant
-
2001
- 2001-06-26 HK HK01104418A patent/HK1034083A1/xx not_active IP Right Cessation
- 2001-12-14 US US10/022,276 patent/US6569837B1/en not_active Expired - Lifetime
-
2003
- 2003-05-13 US US10/438,167 patent/US20030225028A1/en not_active Abandoned
-
2005
- 2005-09-22 US US11/232,818 patent/US7304043B2/en not_active Expired - Lifetime
-
2007
- 2007-05-07 JP JP2007122896A patent/JP2007269798A/ja active Pending
- 2007-05-21 HK HK07105364.0A patent/HK1097776A1/xx not_active IP Right Cessation
- 2007-07-18 LU LU91348C patent/LU91348I2/fr unknown
- 2007-08-06 CY CY200700017C patent/CY2007017I2/el unknown
- 2007-08-09 NL NL300286C patent/NL300286I2/nl unknown
- 2007-09-21 FR FR07C0046C patent/FR07C0046I2/fr active Active
- 2007-10-30 US US11/929,807 patent/US20080064655A1/en not_active Abandoned
-
2008
- 2008-06-24 HK HK08107009.6A patent/HK1111913A1/xx not_active IP Right Cessation
-
2015
- 2015-03-02 CY CY20151100218T patent/CY1116988T1/el unknown